NSCLC

Neoadjuvant nivolumab was safe, and yielded pathologic responses in patients with resectable lung cancer.

The neoadjuvant PD-1 blockade in resectable lung cancer led to major pathological responses in 45 percent of the patients enrolled in a clinical trial.

In the study, the combination of chemotherapy with pembrolizumab performed significantly better in terms of ORR, PFS and OS.

KEYNOTE-189 met its dual primary endpoints of overall survival and progression-free survival in newly diagnosed metastatic NSCLC.

Patients with newly diagnosed advanced NSCLC with high tumor mutational burden had significantly improved PFS with nivolumab plus ipilimumab.